COMPARISON PLATE / 01—04
Four Compounds, Four Evidence Profiles
A side-by-side reading of mechanism, model, maturity, and the question each compound is best equipped to answer.
In plain English
These four compounds share peptide chemistry, but they belong to different branches of research. BPC-157 is mainly an animal repair story. CJC-1295 is an early human hormone-signaling story. GHK-Cu is largely a topical skin and formulation story. KPV is a cell and mouse inflammation story.
That difference is more useful than a simple ranking. A study can be strong for one question and silent on another. CJC-1295 studies show that the long-acting form raises growth hormone and IGF-1, but they do not prove better health or performance [11][12]. GHK-Cu studies can measure topical collagen-related changes or skin penetration without establishing systemic “anti-aging” effects [13][17]. BPC-157 and KPV animal experiments justify continued research without demonstrating clinical benefit [2][20].
The table below compares what each molecule is, where its key evidence comes from, and what remains unsettled. The shared standard is simple: keep each claim attached to its form, model, and measured outcome.
Reference-set comparison
| Compound | Research class | Main proposed route | Strongest evidence in this set | Evidence maturity | Central limitation |
|---|---|---|---|---|---|
| BPC-157 | Gastric pentadecapeptide | VEGFR2, Akt, nitric oxide, cell-migration signals | Rat gastric and tendon repair; mixed vascular models [4][5][6] | Broad preclinical record; tiny human safety observation [1][2] | No rigorous human efficacy trial |
| CJC-1295 | GHRH analog | Pituitary GHRH receptor to GH and IGF-1 | Small human pharmacology studies [10][11][12] | Direct target engagement in people | No mature clinical outcomes or long-term safety base |
| GHK-Cu | Copper-binding tripeptide | Copper transport, fibroblast and matrix signaling | Small topical studies, reviews, and ex vivo skin transport [13][15][16][17] | Limited human topical evidence | Formulation dependence; systemic claims unvalidated |
| KPV | Melanocortin-derived tripeptide | PepT1 uptake; NF-kB and MAP-kinase suppression | Cell systems and mouse colitis models [18][19][20][21] | Preclinical | No published human clinical trial in the corpus |
Mechanism is not a universal score
The mechanisms address different biological levels. BPC-157 research follows vascular and repair signaling around damaged tissue [4]. CJC-1295 acts through an endocrine relay: receptor stimulation in the pituitary raises growth hormone, which then raises IGF-1 [8][11]. GHK-Cu combines metal binding with local matrix and gene-signaling observations [14][16]. KPV is studied as a transported anti-inflammatory fragment that dampens intracellular signaling [20].
No mechanism is inherently “broader” or “better” simply because it touches more pathways. A large list of molecular targets can reflect a broad experimental program, indirect effects, or review-level synthesis. Confidence rises when the same defined material produces a reproducible, meaningful outcome in an appropriate model and then survives well-controlled human testing. By that standard, all four files retain large unanswered areas.
Evidence maturity by question
For human target engagement, CJC-1295 is the most direct file: hormone changes and persistence were measured in small healthy-adult studies [10][11][12]. For topical human relevance, GHK-Cu has the clearest foothold, though small trials, combination products, and skin-delivery constraints limit the reach of the conclusions [13][15][16].
For animal repair biology, BPC-157 has the broadest record here, with rat gastric and tendon findings and vascular-pathway work [4][5][6]. Its two-person safety pilot does not close the gap to human efficacy [1][2]. For preclinical intestinal inflammation, KPV has a coherent series spanning transporter biology, inflammatory signaling, mouse disease models, and targeted delivery [18][19][20][21]. It has no human trial in this set.
Evidence maturity is therefore question-specific. CJC-1295 can lead on measured human pharmacology while remaining unproven for health outcomes. GHK-Cu can have relevant topical observations while lacking systemic evidence. The two animal-centered files can show reproducible biology without supporting human benefit claims.
Safety questions follow the mechanism
The leading cautions also differ. With BPC-157, the primary concern is profound uncertainty, compounded by theoretical questions around angiogenesis and limited independent replication [2][4]. With CJC-1295, sustained GH and IGF-1 signaling focuses attention on fluid balance, glucose regulation, growth signaling, form confusion, and prolonged exposure [11][12].
For GHK-Cu, route and chemical integrity dominate. The topical cosmetic record cannot validate systemic exposure, and intact copper coordination and passage through the skin barrier affect interpretation [13][17]. For KPV, there is too little human information to characterize a clinical safety profile at all. Delivery systems that improve localization in mice do not establish safety in people [18][19].
Across the set, uncertain product identity adds a separate problem outside controlled research. The analytical identification of CJC-1295 in an unknown preparation illustrates why a name on a label is not the same as verified composition [9].
A disciplined way to use the set
The set works best as four linked reference files. Begin with the compound page, note the chemical form and mechanism, then read the findings by model. The final section on each page explains where that file sits relative to the others. The reference register supplies the full source details.
The comparison supports a narrow conclusion: peptide research cannot be judged by category name alone. A fifteen-residue gastric fragment, an albumin-binding hormone analog, a copper chelate, and a three-residue inflammatory fragment demand different questions. Keeping those differences visible is the purpose of Core Peptides Lab.